Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Our vision is to be a world-class commercial biotechnology company. We believe that we can achieve this with an approach of focused excellence in everything that we do-in working efficiently, in making data-driven decisions quickly, and in advancing promising compounds rapidly. Already, we have built one of the most impressive oncology development pipelines in the biotechnology and pharmaceutical industries.
More >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.03
Change (%) Stock is Down 0.24 (5.62%)
Volume5,030,796
Data as of 07/31/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
07/31/14Exelixis Announces Second Quarter 2014 Financial ResultsPrinter Friendly Version
07/16/14Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014Printer Friendly Version
07/14/14Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced MelanomaPrinter Friendly Version
06/03/14Exelixis to Present at the Goldman Sachs 35th Annual Global Healthcare Conference on June 10Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2013 Annual Report (pdf)
Download Documentation2012 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.